Plain-English translation of NCT07580703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new radioactive imaging agent called , which is used during a special type of brain scan (PET scan) to help detect signs of Alzheimer's disease and early memory problems. Researchers want to make sure this medication is safe, understand how it moves through your body, measure the radiation exposure you receive, and see how well it can identify early signs of cognitive decline in Chinese adults.
Early detection of Alzheimer's disease and memory loss is important for potentially slowing progression and helping patients plan their care. This study aims to confirm that this new imaging agent is safe and effective for use in Chinese patients, since most previous testing has been done in other populations.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the radioactive imaging agent and then undergo a PET scan (and possibly an MRI scan) to visualize how the medication distributes in your brain. You may have memory and thinking tests to assess your cognitive status. The study will monitor your safety and measure how much radiation you are exposed to during the imaging process.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China